RECRUITING

CONFIRM: Magnetic Resonance Guided Radiation Therapy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.

Official Title

Clinical Onboard Utilization of Image Guided Radiation Therapy With Magnetic Resonance (CONFIRM): A Master Protocol

Quick Facts

Study Start:2021-05-01
Study Completion:2029-06-18
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04368702

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants must have histologically or cytologically confirmed malignancy requiring radiation
  2. * Age 18 years of older
  3. * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
  4. * Ability to understand and the willingness to sign a written informed consent document.
  5. * Any further criteria listed in the specific disease site cohort
  6. * History of allergic reactions attributed to gadolinium-based IV contrast
  7. * Severe claustrophobia or anxiety
  8. * Participants who cannot undergo an MRI
  9. * Any other exclusion criteria listed in the specific disease site cohort
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Raymond Mak, MD
CONTACT
6177328651
rmak@partners.org

Principal Investigator

Raymond Mak, MD
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Brigham & Women's Hospital
Boston, Massachusetts, 02115
United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02115
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Raymond Mak, MD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-05-01
Study Completion Date2029-06-18

Study Record Updates

Study Start Date2021-05-01
Study Completion Date2029-06-18

Terms related to this study

Keywords Provided by Researchers

  • Gastric Cancer
  • Invasive Breast Cancer
  • in Situ Breast Cancer
  • Lymphoma
  • Larynx
  • Bladder

Additional Relevant MeSH Terms

  • Gastric Cancer
  • Invasive Breast Cancer
  • in Situ Breast Cancer
  • Mantle Cell Lymphoma
  • Larynx Cancer
  • Bladder Cancer